Literature DB >> 1713676

ERCP- and endoscopic sphincterotomy-induced pancreatitis.

S Sherman1, G A Lehman.   

Abstract

Acute pancreatitis may occur after the performance of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy. During ERCP and endoscopic sphincterotomy, the pancreas is subjected to many types of potential injury--mechanical, chemical, hydrostatic, enzymatic, microbiological, allergic, and thermal. These factors may act independently or in concert to induce postprocedure pancreatitis. The potential role of each etiologic factor in the development of ERCP- and endoscopic sphincterotomy-induced pancreatitis is detailed. The management of this complication is reviewed. Patient factors that increase the risk for pancreatitis and techniques to prevent or limit this complication are described. A variety of agents have been shown to prevent or treat pancreatitis in animal models, but extrapolation to humans has been almost uniformly unsuccessful. Although postprocedure pancreatitis is unlikely to be completely eliminated, careful patient selection and attention to detail may reduce the incidence of this untoward event.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713676     DOI: 10.1097/00006676-199105000-00013

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  49 in total

1.  Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial.

Authors:  R T-P Poon; C Yeung; C-L Liu; C-M Lam; W-K Yuen; C-M Lo; A Tang; S-T Fan
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

2.  Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a metanalysis.

Authors:  Suku George; Arvind A Kulkarni; Gary Stevens; Chris E Forsmark; Peter Draganov
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

3.  Effects of probiotic supplementation on markers of acute pancreatitis in rats.

Authors:  Nara L Horst; Ruy Garcia Marques; Cristina F Diestel; Bianca D Matzke; Carlos Eduardo R Caetano; Fernanda Correia Simões; Arnaldo F B Andrade; Wagner I Lobão; Luiz Carlos A Vaz; Margareth C Portela; José Ueleres Braga; Paulo A Melo
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

4.  Admission hematocrit: a simple, useful and early predictor of severe pancreatitis.

Authors:  S Ian Gan; Joseph Romagnuolo
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

5.  Complications of endoscopic retrograde cholangiography in the post-MRCP era: a tertiary center experience.

Authors:  Tze-Zen Ong; Jen-Lock Khor; Dede-Sutedja Selamat; Khay-Guan Yeoh; Khek-Yu Ho
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

6.  Feasibility of the mucosa-tracking technique in precut papillotomy with the iso-tome as an alternative to the needle-knife technique.

Authors:  Sang-Heum Park; Do Hyun Park; Tae Hoon Lee; Ho-Sung Lee; Yong-Sub Lee; Sae Hwan Lee; Chang Kyun Lee; Suck-Ho Lee; Il-Kwun Chung; Hong Soo Kim; Hyo-Jin Lee; Sun-Joo Kim
Journal:  Gut Liver       Date:  2010-03-26       Impact factor: 4.519

7.  Towards safer endoscopic retrograde cholangiopancreatography (ERCP)

Authors:  P B Cotton
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

Review 8.  Complications of diagnostic and therapeutic ERCP.

Authors:  S A Cohen; J H Siegel; F E Kasmin
Journal:  Abdom Imaging       Date:  1996 Sep-Oct

9.  Preoperative assessment for laparoscopic cholecystectomy: feasibility of using spiral computed tomography.

Authors:  A H Kwon; H Inui; A Imamura; S Uetsuji; Y Kamiyama
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

Review 10.  Balloon dilation itself may not be a major determinant of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Sung Ill Jang; Gak Won Yun; Dong Ki Lee
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.